3-chloro-6-hydrazinyl-4,5-dimethylpyridazine | 23130-84-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-chloro-6-hydrazinyl-4,5-dimethylpyridazine
• 英文别名: 6-Chlor-3-hydrazino-4,5-dimethylpyridazin；3-chloro-6-hydrazino-4,5-dimethyl-pyridazine；3-chloro-4,5-dimethyl-6-hydrazinopyridazine；(6-chloro-4,5-dimethylpyridazin-3-yl)hydrazine
• CAS: 23130-84-9
• 化学式: C₆H₉ClN₄
• mdl: MFCD19201374
• 分子量: 172.617
• InChiKey: BTWQGBKWNXRDFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-chloro-6-hydrazinyl-4,5-dimethylpyridazine 在 Molybdenum(III) Reagent 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.25h， 以50%的产率得到3 -氨基- 6 -氯-4,5二甲基哒嗪
  参考文献：
  名称：

  Selective Reduction of Heterocyclic Azides and Hydrazino Compounds to Amines by Molybdenum(III) Species

  摘要：

  DOI：

  10.1055/s-1980-29225
• 作为产物：
  描述：

  2,3-二甲基马来酸酐 在 盐酸肼 、 一水合肼 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 9.0h， 生成 3-chloro-6-hydrazinyl-4,5-dimethylpyridazine
  参考文献：
  名称：

  TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

  摘要：

  这项发明涉及公式I的新化合物， 其中X，A − ，Q1，Q2，Q3，R2，R3，R4，R5，R6，R7，R8和R9分别如下定义。公式I的化合物具有抗血栓活性，特别是抑制蛋白酶活化受体1（PAR1）。该发明还涉及制备公式I化合物的方法以及将其用作药物的用途。

  公开号：

  US20110034452A1

文献信息

• [EN] GPR139 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR139
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2020097609A1

  公开（公告）日：2020-05-14

  Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.

  提供了调节GPR139受体的化合物，含有这些化合物的组合物，以及它们的制备和用于治疗GPR139受体调节在医学上指示或有益的失调的方法。这些化合物具有Formula（X）的结构或其在药学上可接受的异构体，消旋体，水合物，溶剂合物，同位素或盐，其中R1，R2，R3，R4，R9，R10，R11和R12，Q5，Q6，Q7和Q8如本文所定义。
• TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
  申请人：HEINELT Uwe

  公开号：US20110034451A1

  公开（公告）日：2011-02-10

  The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

  该发明涉及公式I的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、Q1、Q2和Q3分别如下定义。公式I的化合物具有抗血栓活性，特别是抑制蛋白酶活化受体1（PAR1）。该发明还涉及制备公式I化合物的方法以及将其用作药物的用途。
• 3,6,7,8-Substituted-s-triazolo[4,3-b]pyridazines as bronchodilators
  申请人：The Dow Chemical Company

  公开号：US04526890A1

  公开（公告）日：1985-07-02

  3,6,7,8-Substituted-s-triazolo-pyridazine compounds such as 7,8-dimethyl-6-morpholino-3-methyl-s-triazolo[4,3-b]pyridazine or 7,8-dimethyl-6-(1-pyrrolidinyl)-3-(isopropyl)-s-triazolo-[4,3-b]pyridazine are prepared by the reaction of a carboxylic acid with a substituted 3-hydrazino-6-halo-pyridazine followed by the reaction of the resulting 6-halotriazolopyridazine with a corresponding base. The compounds have pharmacological activity as bronchodilators.

  3,6,7,8-取代-s-三唑吡啶化合物，如7,8-二甲基-6-吗啉基-3-甲基-s-三唑[4,3-b]吡啶或7,8-二甲基-6-(1-吡咯烷基)-3-(异丙基)-s-三唑-[4,3-b]吡啶，通过羧酸与取代的3-叠氮基-6-卤代吡啶的反应制备，然后通过所得的6-卤代三唑吡啶与相应的碱的反应制备。这些化合物具有支气管扩张剂的药理活性。
• 3,6,7,8-Substituted-s-triazolo(4,3-b)-pyridazines, their preparation and compositions comprising them
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0029130A1

  公开（公告）日：1981-05-27

  3,6,7,8-substituted-s-triazolo-pyridazine compounds of the formula wherein R3 represents hydrogen or loweralkyl, R6 represents amino, loweralkylamino, diloweralkylamino, heterocyclic amino or lower alkyl substituted heterocyclic amino, wherein the heterocyclic moiety forms a 5, 6 or 7 membered ring, having one or two ring nitrogen atoms and zero or one ring sulfur or oxygen atom; T7 represents loweralkyl; R8 represents hydrogen or loweralkyl; or R7 and R8 taken together represent polymethylene of 3 or 4 methylene units or polymethylene substituted by lower alkyl, or methano or ethano bridges; and their pharmacologically acceptable salts are made by reacting a carboxylic acid with a substituted 3-hydrazino-6-halo-pyridazine and then reacting the resulting 6-halotriazolopyridazine with a corresponding base. The compounds have pharmacological activity as bronchodilators.

  式中，R3代表氢或低碳基，R6代表氨基，低碳基氨基，二低碳基氨基，杂环氨基或低碳基取代的杂环氨基，其中杂环基形成一个5、6或7个成员的环，有一个或两个环氮原子和零或一个环硫或氧原子；T7代表低碳基；R8代表氢或低碳基；或R7和R8一起代表3或4个亚甲基单元的聚甲基或低碳基取代的聚甲基，或甲烷或乙烷桥；它们的药物学可接受盐是由羧酸与取代的3-肼基-6-卤代吡啶嗪反应，然后将得到的6-卤代三唑吡啶与相应的碱反应制得的。这些化合物具有支气管扩张剂的药理活性。
• Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
  申请人：Sanofi-Aventis

  公开号：US08076336B2

  公开（公告）日：2011-12-13

  The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

  本发明涉及公式I的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、Q1、Q2和Q3分别如下定义。公式I的化合物具有抗血栓活性，特别是抑制蛋白酶活化受体1（PAR1）。本发明还涉及制备公式I化合物的方法以及将其用作药物的用途。